|
Performance indicator
|
Invitation round
|
|---|
|
First 2008–2009%
|
Second 2010–2011%
|
Third 2012–2013%
|
Fourth 2014–2015%
|
|---|
|
Coverage of examination
|
75.4 (75.3–75.5)
|
75.0 (74.8–75.1)
|
76.7 (76.6–76.8)
|
76.4 (76.3–76.5)
|
|
Participation after invitation
|
76.4 (76.3–76.5)
|
81.8 (81.7–81.9)
|
84.3 (84.3–84.4)
|
82.1 (82.0–82.2)
|
|
Detection rate
|
0.93 (0.91–0.96)
|
0.62 (0.60–0.64)
|
0.67 (0.65–0.69)
|
0.61 (0.59–0.64)
|
|
False-positive rate
|
2.04 (2.00–2.08)
|
2.08 (2.04–2.12)
|
2.07 (2.03–2.11)
|
1.88 (1.84–1.92)
|
|
Invasive
|
87.5 (86.5–88.4)
|
86.3 (85.0–87.5)
|
86.4 (85.2–87.4)
|
85.8 (84.5–86.9)
|
|
DCIS
|
12.6 (11.6–13.5)
|
13.7 (12.5–15.0)
|
13.6 (12.6–14.8)
|
14.2 (13.1–15.5)
|
|
Lymph node neg
|
69.8 (68.4–71.2)
|
74.5 (72.8–76.2)
|
78.2 (76.7–79.6)
|
80.4 (78.8–81.8)
|
|
Small tumor
|
36.1 (34.4–37.8)
|
40.1 (38.2–42.1)
|
39.8 (38.0–41.5)
|
40.1 (38.3–42.0)
|
|
Interval cancer rate
|
17.9 (16.9–19.1)
|
28.9 (27.3–30.5)
|
26.3 (24.9–27.8)
|
NA
|
|
Sensitivity
|
82.1 (81.1–83.1)
|
71.2 (69.8–72.5)
|
73.7 (72.5–74.8)
|
NA
|
|
Specificity
|
97.9 (97.9–98.0)
|
97.9 (97.9–97.9)
|
97.9 (97.9–98.0)
|
NA
|
- Notes:
-
NA not available
- Percent and 95% confidence intervals
